Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Novo Nordisk's Wegovy consumption jumped 70% after price cuts, lifting share in November. Eli Lilly's Mounjaro still led anti ...

Dec 2 () - Wegovy maker Novo Nordisk is planning ​to test its experimental obesity drug, ‌CagriSema, in overweight children ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Novo Nordisk ( NVO 2.28%) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...